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• CRISPR/Cas9 is the method of choice for site-directed genetic or transcriptional manipulation 
• Genomic loci differ in chromatin configuration which affects Cas9 functioning  
• 5-cytosine DNA methylation does not directly impair Cas9 binding/cleavage  
• Nucleosomes can completely block Cas9 access in cell-free assays and present a substantial 
hurdle in vivo 
• Active gene transcription can increase Cas9 cleavage efficiency independent of chromatin 
parameters  
Abstract 
CRISPR/Cas technologies have rapidly become routine in many laboratories. Despite this, the 
efficiency of CRISPR/Cas9 functioning cannot entirely be predicted, and it is not fully understood which 
  
factors contribute to this variability. Recent studies indicate that heterochromatin can negatively 
affect Cas9 binding and functioning. Investigating chromatin factors indicates that 5-cytosine 
methylation does not directly block Cas9 binding. Nucleosomes, however, can completely block Cas9 
access to DNA in cell-free assays and present a substantial hurdle in vivo. In addition to being 
associated with an open chromatin state, active transcription can directly stimulate DNA cleavage by 
influencing Cas9 release rates in a strand-specific manner. With these insights and a better 
understanding of genome-wide chromatin and transcription states, CRISPR/Cas9 effectiveness and 
reliability can be improved.  
Introduction 
Sequence-specific DNA targeting proteins form the cornerstone of increasingly common techniques 
to modify specific genomic loci at will. The Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR/Cas9) system, originally found in Streptococcus pyogenes, has become the most widely 
adopted DNA targeting platform [1,2]. However, despite many algorithms and sgRNA design tools, 
there is much-unexplained variability in efficiencies, even between the same target sequences in 
different cell types. Furthermore, it has been observed that sgRNAs performing well in vitro can 
underperform in vivo [3] and that partially matching off-target DNA sequences can exhibit higher Cas9 
cleavage rates than their fully matching on-target site [4–6]. These results suggest that factors beyond 
the sgRNA/target sequence influence Cas9 functioning.  
Recent work indicates that the way DNA is modified and packaged in the nucleus – collectively referred 
to as chromatin state – can have significant effects on Cas9 binding and may help explain variation in 
functional efficiency. ChIP-seq screens found dCas9 off-target binding to be enriched in open 
chromatin [7–10], and chromatin accessibility has been found to positively correlate with CRISPR/Cas9 
efficiency [11].  Importantly, not only the binding of (d)Cas9 may be affected by the local chromatin 
state, but also the intended outcome. 
Understanding the role of chromatin in genome targeting applications is especially important when 
chromatin states differ between experimental models and intended applications (e.g. cell cultures 
may not resemble target cells in patients). Here, we review the influence of chromatin states on Cas9 
functioning. We contrast cell-free (generally chromatin-free) assays and in vivo experimental evidence 
and discuss strategies to increase Cas9 efficiency. 
(d)Cas9 and 
sgRNA 
Cas9 is a protein with intrinsic nuclease activity that cuts a specific DNA 
sequence via base complementarity using a short RNA molecule called the 
single guide RNA (sgRNA). The nuclease complex can be retargeted to another 
genomic locus simply by changing the sgRNA sequence. Since its introduction 
as a genome-editing tool in 2012 [12,13], Cas9 has been adapted for far more 
than just site-directed DNA cleavage. Most commonly this is achieved through 
the direct fusion of effectors to a nuclease deactivated Cas9 (dCas9) to allow 
for site-directed effects such as transcriptional modification. 
Euchromatin and 
heterochromatin 
Chromatin refers to a cell’s DNA and its associated macromolecules and 
modifications. Euchromatin describes segments of chromatin that are 
relatively unpacked and accessible to regulatory factors. In contrast, 
  
heterochromatin consists of densely packed nucleosomes, crowded by non-




DNase hypersensitivity reflects open chromatin states by measuring the 
accessibility of DNA to the DNase I enzyme. Euchromatin is more prone to 
cleavage than regions of heterochromatin.  
ChIP-seq Chromatin Immunoprecipitation sequencing (ChIP-seq) is a method to identify 
the sequences at which a protein or protein complex interacts with DNA. In 
the context of this review, (d)Cas9 can be crosslinked to and isolated with DNA 
it has (transiently) bound, and the location can be identified by mapping the 
sequences back to the genome.  
 
 
Heterochromatin states can impede Cas9 access  
The best controlled experimental evidence of chromatin influence on Cas9 editing outcomes and 
binding comes from studying otherwise identical sgRNA target sequences with allele-specific 
chromatin states. For example, three sgRNAs were targeted to the CpG Island (CGI) containing 
p16INK4a locus, of which the two alleles have different chromatin states in HCT116 cells: one 
repressed (hypermethylated), the other expressed (hypomethylated) [14]••. Sequencing of individual 
clones showed that for two of the three sgRNAs there was no significant difference in Cas9 
mutagenesis rate between the two alleles. The third sgRNA did show a significant difference: of the 
18 screened clones, 2/18 had a mutation in the repressed allele, and 17/18 had a mutation at the 
transcriptionally active one. This preference was also reflected in a lower Cas9 binding on the 
heterochromatin allele over the euchromatin allele.  
Similar to the above study, Kallimasioti-Pazi and colleagues targeted CGIs on differentially imprinted 
alleles [15]••: the repressed heterochromatin maternal allele accumulated Cas9-mediated mutations 
slower than the paternal allele. The most substantial difference in mutagenesis was observed when 
Cas9 exposure was brief and when intracellular Cas9 expression was low. More subtle effects were 
observed for higher Cas9 expression levels.  
Heterochromatin-euchromatin differences comprise a heterogeneous mix of many factors. Separating 
the contribution of individual factors is challenging and depends on modulating single chromatin 
components with in vitro assays. To date DNA methylation and nucleosome occupancy have been the 
best studied and below we evaluate their effect on functional Cas9 binding.  
 
5-Methylcytosine does not directly hinder Cas9 binding  
Cleavage of DNA by Cas9 can be susceptible to modifications at the site of gRNA:DNA hybridisation. 
For example, the presence of large glucosylated hydroxymethylcytosine in the DNA target site of Cas9 
allows T4 phages to escape Cas9-mediated bacterial immunity [16,17], although this can depend on 
how the gRNA is designed [17,18]. Methylation of T4 DNA target sites was not found to protect the 
phages [18]. Likewise, a cell-free Cas9 cleavage assay confirmed complete cleavage of both 
methylated and unmethylated DNA and three tested sgRNAs induced mutations at a methylated locus 
in cells [19]••. Similarly, using dCas9 fused to transcriptional activators, hypermethylated loci could 
  
successfully be activated [20,21]. The absence of direct effects of DNA methylation was further 
demonstrated by studying the differentially methylated p16INK4a alleles in HCT116 cells [14]: by using 
purified genomic DNA (maintaining DNA methylation while removing other chromatin factors), the 
binding preference observed in vivo for the hypomethylated p16INK4a allele was lost. 
For suboptimal, relatively weakly-binding off-targets, CpG methylation might play a role: a 
bioinformatic analysis identified DNase hypersensitivity as the strongest predictor of off-target 
binding for four different sgRNAs [8]•. However, considering sites containing CpG dinucleotides, CpG 
methylation negatively correlated with binding and became the strongest predictor of dCas9 binding. 
These data suggest that CpG methylation reflects chromatin accessibility beyond DNase 
hypersensitivity and that CpG methylation (indirectly) affects binding at off-target sites [22].  
The effect of methylation is further nuanced by its microchromatin context as we described for dCas9 
and zinc-finger fusions to VP64 [23]. Like earlier studies, dCas9-VP64 -even when targeted to 
methylated sites- effectively upregulated genes. However, methylated target sites located in CGIs 
seemed recalcitrant to dCas9-VP64 upregulation. This difference was reflected in reduced binding as 
measured by ChIP-seq.  Interestingly, targeting VP64 with smaller zinc finger proteins to these same 
sites within the methylated CGIs did result in upregulation of transcription. This finding supports the 
idea that not CpG methylation of the target sequence itself, but the recruited methylation-associated 
factors affect Cas9 binding   
In summary, methylation does not seem to have a direct effect on Cas9 binding or effectivity. If it does, 
it is likely weak and may only be detected under sub-optimal conditions. However, in vivo CpG 




The most common modification to DNA in mammals is the methylation of 
cytosine, forming 5-methylcytosine (5-mC). Importantly, differential DNA 
methylation has been recognised as a disease mechanism, for example cancer 
or immune disorders [24,25]. Therefore, these regions have been forwarded 
as potential therapeutic targets for engineered DNA-targeting platforms 
highlighting the importance of understanding the influence of DNA 
methylation on Cas9 functioning [1]. 
CpG islands 
(CGIs) 
Short stretches of CpG (cytosine nucleotide followed by guanine) rich DNA are 
termed are CpG islands. For CpG islands in promoter regions, 
hypermethylation associates with gene inactivation. 
 
Nucleosomes can completely block functional Cas9 binding to DNA in cell-
free assays but are more tolerant in vivo 
To find a mechanistic basis for the effects of chromatin on functional Cas9 binding, research has 
focussed on the smallest unit of chromatin organisation, the nucleosome. In cell-free assays, the 
packaging of DNA in nucleosomes impedes DNA cleavage by Cas9, presumably by hindering access to 
the DNA and preventing efficient binding [9,26,27]. DNA at the entry or exit sites of nucleosomes can 
  
be less shielded than sites at the centre of the nucleosome to which access is almost abolished [26,27]. 
However, another study found complete obstruction along the full length of the nucleosomal DNA [9].  
Although these in vitro assays mostly make use of DNA substrates with artificially strong nucleosome 
positioning sequences resulting in strong, stable nucleosomes, most cellular nucleosomes are 
dynamic. Nucleosome “breathing” is assumed to occur frequently and refers to the temporary 
unwrapping of stretches of nucleosomal DNA, and may thereby shortly expose these DNA sequences 
to binding by (d)Cas9. Indeed, when a natural nucleosome positioning sequence was investigated the 
DNA was found to be far more permissible to Cas9 cleavage near the nucleosome edge [26]. However, 
the DNA at the centre of the nucleosome remained almost completely resistant to cleavage. Upon 
chromatin remodelling, the nucleosomal DNA, otherwise inaccessible to Cas9 cleavage, became a 
viable substrate in these cell-free systems [9,26].  
Engineered cells in which local heterochromatin formation can be induced or reversed [28,29] 
demonstrated that targeting the same site under a more relaxed chromatin structure increased Cas9-
mediated mutagenesis. Bioinformatics analysis indicated that while nucleosomes allow binding and 
cutting in vivo, sgRNAs classified as highly effective were predominantly found in low nucleosome 
occupancy regions [9].  
Together, these results point to a model in which functional Cas9 binding is strongly occluded by 
nucleosomes, but access can be gained during natural nucleosome remodelling and breathing [11,26]. 




Nucleosomes are the primary constituent of chromatin, being formed of 147 
pbs of DNA wrapped around a complex of eight histone proteins.  
 
Genetic and epigenetic editing outcomes can be affected by target chromatin 
states 
Under certain conditions not only the binding of the Cas9 complex may be affected by the local 
chromatin state, but also the functional outcome of the treatment. We have observed this when 
studying the effect of epigenetic editors fused to dCas9. Targeting methylated or unmethylated sites 
can result in a difference in the length of time transcriptional upregulation of a gene is sustained. This 
is likely not due to the efficiency of editing but instead reflects the permissiveness of the local 
chromatin state for maintaining the newly introduced epigenetic mark [23]. Likewise, the observed 
differences in Cas9 gene editing efficiency at heterochromatin sites may in part be due to changes in 
repair outcomes. Differential repair fidelity or dynamics could result in different perceived rates of 
mutagenesis without reflecting Cas9 inaccessibility.  
Although numerous studies have evaluated Cas9 mediated mutagenesis, few explicitly report the 
chromatin state of the target and even fewer perform well-controlled comparisons between the same 
site under differing chromatin states. Those studies that do, show no apparent differences in effects. 
For example, no significant difference was found in the ratio of homology-directed repair over error-
  
prone non-homologous end joining repair for the same locus on the two alleles with different 
chromatin states and mutation patterns were similar [15]. The same was found using an inducible 
heterochromatin assay: while the rate of mutagenesis was severely affected by the closed chromatin, 
the resulting mutations were similar [29]. These results are surprising, as chromatin states have been 
found to affect endogenous DNA repair in complex ways [30]. 
Kallimasioti-Pazi et al. speculated that the chromatin remodelling events associated with Cas9 binding 
might obscure differences in repair outcomes [15]. This is supported by studies finding that dCas9 
binding results in locally increased chromatin accessibility, which even increases editing efficiencies of 
other co-delivered Cas constructs [31–33]. The authors noted that during early points in their time 
course experiments (<24 h) a higher proportion of the mutations on the heterochromatin allele were 
single nucleotide deletions compared to the open chromatin allele. This time-dependent phenomenon 
has previously been observed by Overbeek et al. and is likely due to re-cutting of smaller mutations 
despite sgRNA mismatches [34].  
Finally, it has been noted that the transcriptional state of a gene can correlate with editing efficiency 
[3]. However, it is challenging to disentangle transcription from chromatin factors that vary with 
transcriptional state. Interestingly, a recent study found that only particular sgRNAs showed higher 
mutation rates targeting a transcriptionally activated gene compared to its uninduced state [35]••.   
Cas9:sgRNA complexes that directly base-paired to the DNA strand serving as a template for RNA 
polymerase, not those binding the complementary strand, showed an increase in mutagenesis rate. 
Excluding chromatin effects with in vitro transcription assays showed that RNA polymerases could 
displace specifically oriented Cas9 proteins from DNA, freeing them to cut other DNA molecules in the 
solution. The authors suggest that the dislodging of Cas9 by the RNA polymerase exposes the cut ends 
which increases the opportunity for error-prone repair or additional cleavage events on transcribed 
genes. However, this phenomenon cannot account for all chromatin-related effects on Cas9. In the 
study by Fujita et al. the only sgRNA that showed a difference between the open and closed allele 
should not have been affected by sense transcription of the targeted gene [14]. Moreover, a sgRNA 
targeted nearby in the same orientation showed no significant difference in targeting efficiency 
between the two alleles. Notwithstanding, Cas9 displacement by RNA polymerases is an exciting new 
finding and should be taken into account in future studies investigating the influence of chromatin 
state on Cas9.   
Conclusions 
Current evidence points towards chromatin states playing a significant role in Cas9 binding and 
functioning. CpG methylation does not seem to affect Cas9 binding and cleavage directly. However, 
CpG methylation may correlate with other factors that can obstruct Cas9, with limited evidence 
indicating this may be especially important in CGI contexts. Conceptually, the methylation in a CpG 
island context may result in the recruitment of methyl-binding proteins and chromatin remodelers 
that are not attracted to the same extent by more sporadic methylation. Nucleosomes show a clear 
and robust ability to obstruct Cas9 cleavage in cell-free assays, while in vivo nucleosomes seem more 
dynamic allowing nucleosomal DNA to be more permissive for Cas9 cleavage. These findings are 




Figure 1:   The influence of chromatin factors on functional Cas9 binding. This takes into account both 
direct evidence of binding and indirect evidence from functional outcomes such as mutagenesis by Cas9 
or transcriptional modulation by dCas9 fusions to effector domains. The various methyl-binding 
proteins, massively recruited to CpG islands when methylated, are only indicated as sporadic 
complexes. Note that this is schematic: relative sizes of DNA, methyl groups (+), histones, and Cas9 are 
not accurate. 
More broadly, heterochromatin can substantially obstruct Cas9 mediated editing, especially under 
suboptimal conditions such as low Cas9 expression, inefficient sgRNAs, or partial mismatches. The 
repair results of Cas9 based editing in euchromatin and heterochromatin are more similar than 
expected, warranting further investigation. Finally, transcription can have its own positive effect on 
Cas9 editing by displacing Cas9, increasing the rate at which cut ends are exposed but possibly having 
an inhibitory effect on some dCas9-based applications where extended binding is beneficial.    
The practical consequences of the experimental results discussed in this review are that the chromatin 
and transcriptional state of a target site should be taken into account when translating in vitro CRISPR 
experiments to in vivo situations. In vitro assays can assist in identifying highly active sgRNAs but 
cannot predict general applicability given the impact of chromatin factors on Cas9 functioning. 
Although gene editing of an actively transcribed locus seems rather straightforward and gene 
modulation studies use combinations of sgRNAs, studies relying on effects of individual or few sgRNAs 
have to be carefully interpreted. Future sgRNA design tools should exploit available databases on 
chromatin context and gene transcription such as www.encodeproject.org or ihecepigenomes.org to 
increase Cas9 reliability. Importantly, chromatin effects should be better taken into account during 
experimental design: inclusion of appropriate controls will provide insights and minimise 
overestimations of general applicability of any given sgRNA.  
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